Table 3.
In vitro-determined antifungal and hemolytic activities of the genetically engineered S44HP analoguesd
| Compound | Mutation(s) | MIC (μg/ml)a | HC50 (μg/ml)b |
|---|---|---|---|
| AmB | None | 0.18 ± 0.03 | 3.0 ± 0.25 |
| S44HP | ER5 | 0.19 ± 0.03 | 3.0 ± 0.25 |
| BSG005 | ER5 NysN | 0.11 ± 0.03 | 4.0 ± 0.3 |
| BSG003 | ER5 DH15 | 12.0 ± 0.60 | >600c |
| BSG018 | ER5 NysN DH15 | 9.0 ± 0.45 | >200c |
| BSG022 | ER5 NysL | 0.20 ± 0.02 | 1.4 ± 0.15 |
| BSG019 | ER5 NysN NysL | 0.12 ± 0.03 | 4.5 ± 0.3 |
a
Tested as described in reference 7, using C. albicans as test organism and with 22-h exposure time.
b
Tested as described in reference 7, using defibrinated horse blood cells and antibiotic concentrations ranging between 0 and 600 μg/ml.
c
For BSG003, 13% hemolysis was observed at the highest concentration tested (600 μg/ml); for BSG018, 3% hemolysis was observed at the highest concentration tested (200 μg/ml).
d
The ± values represent maximum deviation from the mean.